Gabather

0.04 SEK

+13.97 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+13.97 %
-22.73 %
+46.76 %
+48.91 %
+31.61 %
+1.49 %
-96.47 %
-97.15 %
-99.04 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Read more
Market cap
24.91M SEK
Turnover
59.32K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29/5
2026

Interim report Q1'26

26/6
2026

General meeting '26

31/8
2026

Interim report Q2'26

ShowingAll content types
Third party research

Gabather: Key shareholders show support - VH Corp

* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigger * We keep our fair value of SEK 0.06 per share Gabather has carried out a directed share issue of approximately MSEK 4.2 with participation from several...

Gabather

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Gabather: Any day now - VH Corp

* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our fair value amounts to SEK 0.06 per share Gabather’s Q4 report showed lower-than-expected costs, primarily due...

Gabather
Third party research

Gabather presents Q4 2025 - VH Corp

CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Västra Hamnen's analyst Jacob Murat.

Gabather
Third party research

Gabather: Eager to start the TOTEMS study - VH Corp

* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...

Gabather
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.